Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?

Stroke. 2004 Feb;35(2):389-91. doi: 10.1161/01.STR.0000115528.53718.1B.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III
  • Comparative Study
  • Editorial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use*
  • Atrial Fibrillation* / complications
  • Azetidines / adverse effects
  • Azetidines / therapeutic use*
  • Benzylamines
  • Canada
  • Double-Blind Method
  • Hemorrhage / chemically induced
  • Humans
  • Risk
  • Stroke / etiology
  • Stroke / prevention & control*
  • Thrombin / antagonists & inhibitors
  • Treatment Outcome
  • United States
  • Vitamin K / antagonists & inhibitors
  • Warfarin / adverse effects
  • Warfarin / therapeutic use*

Substances

  • Anticoagulants
  • Azetidines
  • Benzylamines
  • Vitamin K
  • ximelagatran
  • Warfarin
  • Thrombin